Post-Covid: elective procedures long re-start, telehealth explosion, reduced investments
Hospital & Health system survey give key insights for Pharma and Medtech business re-start :
- elective procedure volumes will not return to normal before early 2021
- majority of providers anticipate 5 fold increase in telehealth, but only 1/3 believe they are ready
- cost savings expected primarily through reduced acquisitions of high-cost medical equipment and technology
Each Pharma and Medtech company needs to support its customers in preparing their re-start plan, and adapt their operating model accordingly.
